New research indicates that 3-D cell culturing technology developed by
Rainbow Coral Corp. (OTCBB: RBCC) partner Nano 3D BioSciences (n3D)
could make toxicity tests for airborne chemicals faster and more
effective than ever before.
In collaboration with scientists at Rice University, Dr. Glauco Souza of
n3D led a research study that demonstrates the potential of the
company’s magnetic levitation tech to grow some of the most realistic
lung tissue produced in a laboratory. In the study, researchers combined
four types of human cells to replicate three-dimensional tissues from
the wall of the bronchiole, found deep inside the lung.
Using traditional 2-D cell cultures, producing cells at the air-liquid
interface, ideal for toxicity testing, is enormously difficult. Using
n3D technology, however, researchers were able to magnetically levitate
bronchiole tissue to the air-liquid interface so that airborne toxins
can be exposed to the epithelial layer of the tissue, just as would
occur in human lungs.
The same methods have also been used to culture heart valve tissue. RBCC
believes that its joint venture partner’s technology is on the cusp of
becoming standard equipment in cellular research labs around the globe.
“Scientists everywhere are discovering that n3D’s Bio-Assembler
technology can produce superior cell cultures for a broad range of
research fields,” said RBCC CEO Patrick Brown. “As more and more
high-profile cell researchers discover this system’s potential, the
market for the technology will continue to grow exponentially.”
The Bio-Assembler’s fusion of magnetic levitation and nanoparticle
assembly technology allows it to produce accurate, 3D representations of in
vivo tissues faster and easier than any other existing tools. The
incredible device is key to RBCC’s plans to participate in the
impressive upside in store for n3D.
“Previously, when I worked at Baylor College of Medicine, we used
transwells to study human bronchial epithelial cells,” said n3D
scientist Jacob Gage, who co-authored the bronchiole study. “After
switching to the Bio-Assembler, we were able to culture multiple cell
types to generate an in vivo-like environment. This gave us the
opportunity to create truly three-dimensional and histologically
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb
Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories
(NYSE: ABT) and Amgen, Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com].
For investment information and performance data on the company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.